Zotiraciclib citrate
Product Specifications
CAS Number
1204918-73-9
Bioactivity
Zotiraciclib (also known as TG02 and SB1317) is an innovative small-molecule compound with potent inhibitory effects on CDK, JAK2, and FLT3. By inhibiting cyclin-dependent kinase 9 (CDK9) and depleting Myc, it serves as a treatment for cancers that can penetrate the blood-brain barrier. Zotiraciclib is one of the numerous CDK inhibitors under investigation; other compounds targeting CDK9, utilized for treating acute myeloid leukemia, include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80% of glioblastomas exhibiting this characteristic.
Smiles
OC(=O)CC(O)(CC(O)=O)C(O)=O.CN1C\C=C\CCOC2=CC(=CC=C2)C3=CC=NC(NC4=CC=CC(C1)=C4)=N3
Molecular Formula
C29H32N4O8
Molecular Weight
564.59
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP304277 20 µg
Oncostatin M (OSM) (NM_020530) Human Recombinant Protein
Sign In for Pricing
View Details K1784508 1.0 µg DNA
RANGRF sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
Sign In for Pricing
View Details LY415970 100 µg
CCRK (CDK20) (NM_012119) Human Over-expression Lysate
Sign In for Pricing
View Details 